Articles tagged "Highly-sensitized"

2020 American Transplant Congress
Third and Fourth Kidney Re-Transplants: A 20-Year Single Centre Experience
O. O. Okidi¹, A. Hassan¹, S. Bhutani¹, A. Summers¹, K. Poulton², C. Fullwood¹, D. VanDellen¹, J. Worthington², T. Augustine¹
¹Transplant and Endocrine Surgery, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ²Transplantation Laboratory, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, United Kingdom
*Purpose: Re-transplantation may be associated with management dilemmas including repeat allocation of limited kidney allografts to same individuals in the face of an increasing waiting…
2020 American Transplant Congress
Anti-HLA IgM Antibodies are Unaffected by Imlifidase (IdeS) Treatment
A. Runström¹, R. Bockermann¹, K. Sjöholm¹, K. M. Roupé¹, Å. Schiött¹, L. Winstedt¹, C. Kjellman¹, T. Lorant²
¹Hansa Biopharma AB, Lund, Sweden, ²Section of Transplantation Surgery, Department of Surgical Sciences, Uppsala, Sweden
*Purpose: The immunoglobulin G (IgG)-degrading cysteine protease, imlifidase (IdeS) is an IgG endopeptidase under development as a rapid desensitization treatment in kidney transplantation. Imlifidase is…
2020 American Transplant Congress
Outcomes of Post-Transplant Desensitization in High Immunological Risk Deceased Donor Kidney Transplant Recipients
D. Kumar, C. Song, L. Kamal, I. Moinuddin, M. Levy, C. Bhati, A. King, P. Kimball, G. Gupta
Virginia Commonwealth University, Richmond, VA
*Purpose: The kidney allocation system (KAS) was changed in 2015 to increase access to transplants for highly sensitized patients. However, recent data suggests that even…
2020 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Williamson¹, C. Meyers¹, S. Sethi¹, K. Lim¹, J. Choi¹, S. C. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 mediates inflammation and activation of T-cells, B-cells & plasma cells. Thus, IL-6 may represent an important target for desensitization (DES). Here we report…
2020 American Transplant Congress
Infectious Complications in Elderly Kidney Transplant Recipients Undergoing Desensitization
S. Sethi, R. Najjar, A. Peng, A. Vo, S. Jordan, E. Huang
Cedars Sinai Medical Center, West Hollywood, CA
*Purpose: Data is limited on the impact of desensitization on infectious complications in elderly kidney transplant (KT) recipients. We examined infectious complications in elderly KT…
2020 American Transplant Congress
Preformed Anti-HLA Donor-Specific Antibodies Immunological Risk Assessment: The Importance of HLA Antibody Locus-Specificity
V. Jucaud¹, A. Babu², D. Briggs³, N. Krishnan⁴, D. Mitchell⁵, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ³NHS Blood and Transplant, Birmingham, United Kingdom, ⁴University Hospitals Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ⁵University of Warwick Medical School, Coventry, United Kingdom
*Purpose: The screening of preformed donor-specific HLA antibodies (pfDSA) by single antigen bead assays has increased the complexity of pre-transplant patient risk stratification. We evaluated…
2019 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962)
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamsons, C. Myers, K. Lim, J. Choi, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Currently, there is growing interest in development of novel immune-modulatory drugs likely to improve allo-antibody reduction in transplantation. Clazakizumab (Vitaeris Inc.) is a humanized…
2019 American Transplant Congress
Outcomes in Preformed Donor-Specific Human Leukocyte Antibody Positive Living Kidney Transplant Recipients Desensitized with Intravenous Immunoglobulin and Rituximab
Y. kakuta¹, M. Okumi¹, T. Kanzawa¹, K. Unagami², H. Ishida², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Donor-specific antibody (DSA) is associated with antibody-mediated rejection (ABMR) and is a significant immunologic barrier to graft and patient survival. Pre-transplant desensitization therapy has…
2019 American Transplant Congress
Safety and Efficacy of Imlifidase in Highly-Sensitized Kidney Transplant Patients: Results from a Phase 2 Study
S. C. Jordan¹, C. Legendre², N. Desai³, T. Lorant⁴, M. Bengtsson⁴, L. Laxmyr⁵, B. Lonze⁶, A. Vo¹, K. J. Wood⁷, C. Kjellman⁵, R. A. Montgomery⁶
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Hopital Necker, Paris, France, ³Johns Hopkins University, Baltimore, MD, ⁴Uppsala University, Uppsala, Sweden, ⁵Hansa Medical AB, Lund, Sweden, ⁶NYU Langone Health Transplant Institute, New York, NY, ⁷University of Oxford, Oxford, United Kingdom
*Purpose: Many patients eligible for kidney transplantation are sensitized to allo-HLA antigens and face prolonged waiting times and increased mortality. The presence of donor specific…
2019 American Transplant Congress
Hepatitis Flare in Hepatitis B Core Antibody Positive Kidney Recipients Treated with Rituximab
M. Raja¹, Y. Natori¹, C. Donato¹, D. De Lima¹, J. Rivollo², A. Centeno², Y. Ebisu¹, L. Abbo¹, J. Simkins¹, S. Anjan¹, J. Camargo¹, M. I. Morris¹
¹Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, ²Jackson Memorial Hospital, Miami, FL
*Purpose: Patients with Hepatitis B Core Antibody (anti-HBc Ab) positive are known to be at risk for Hepatitis B virus (HBV) reactivation during periods of…

« Previous Page
1
…
3
4
5
6
7
…
15
Next Page »